Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 4, 2002, Pages 453-460

  Furuta, Takahisa ^{a,b,c,d,e,f,g}   Shirai, Naohito ^{a,b,c,d,e,f,g}   Watanabe, Fumitoshi ^{a,b,c,d,e,f,g}   Honda, Satoru ^{a,b,c,d,e,f,g}   Takeuchi, Ken ^{a,b,c,d,e,f,g}   Iida, Takayuki ^{a,b,c,d,e,f,g}   Sato, Yoshihiko ^{a,b,c,d,e,f,g}   Kajimura, Masayoshi ^{a,b,c,d,e,f,g}   Futami, Hajinie ^{a,b,c,d,e,f,g}   Takayanagi, Shigekazu ^{a,b,c,d,e,f,g}   Yamada, Masami ^{a,b,c,d,e,f,g}   Ohashi, Kyoichi ^{a,b,c,d,e,f,g}   Ishizaki, Takashi ^{a,b,c,d,e,f,g}   Hanai, Hiroyuki ^{a,b,c,d,e,f,g}  

^a HAMAMATSU UNIVERSITY   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^c HAMAMATSU MEDICAL CENTER   (Japan)

^d FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^e Kikugawa General Hospital   (Japan)

^f Fujinomiya City General Hospital   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; ENDOSCOPY; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036795262     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127637     Document Type: Article

References (36)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastro-esophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
2. Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9:15-25.
3. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
4. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
5. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
6. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 1997;61:574-82.
7. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl 1):S21-5.
8. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
9. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995;58:143-54.
10. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
11. Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60:157-67.
12. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18:721-7.
13. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552-61.
14. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001;70:484-92.
15. Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002;16:837-46.
16. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001;15:1929-37.
17. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000;119:670-6.
18. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000;14:1259-66.
19. Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F, et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001;18:615-21.
20. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129: 1027-30.
21. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8.
22. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69: 158-68.
23. Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999;34:80-3.
24. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999;66:528-34.
25. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92.
26. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
27. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism. in Japanese. Mol Pharmacol 1994;46:594-8.
28. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6.
29. Aoki I, Okumura M, Yashiki T. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J Chromatogr 1991;571:283-90.
30. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93: 763-7.
31. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001;16:1191-6.
32. Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990;4:485-95.
33. Leite LP, Johnston BT, Just R J, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-31.
34. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999;9:539-49.
35. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-6.
36. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.